Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Diamond

Showing results (321-330 of 344) with videos related to

Pageof 35
Sort By:
Cancer Research Communications|April 6, 2026
Metastasis-Associated Wound Repair Promotes Reciprocal Lung Epithelium Activation and Breast Cancer Metastatic OutgrowthJessica L Christenson, Nicole S Spoelstra, Michelle M Williams, et al.
Biorxiv : the Preprint Server for Biology|December 16, 2024
Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breastJoseph L Sottnik, Madeleine T Shackleford, Camryn S Nesiba, et al.
Cancer Research Communications|March 11, 2026
Metastasis-associated wound repair promotes reciprocal lung epithelium activation and breast cancer metastatic outgrowthJessica L Christenson, Nicole S Spoelstra, Michelle M Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2019
Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4Priscilla K Stumpf, Diana M Cittelly, Tyler P Robin, et al.
Cancer Research|January 9, 2026
Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP InhibitionJoseph L Sottnik, Madeleine T Shackleford, Camryn S Nesiba, et al.
Journal of Neurotrauma|January 8, 2021
Tractography-Pathology Correlations in Traumatic Brain Injury: A TRACK-TBI StudyAmber L Nolan, Cathrine Petersen, Diego Iacono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast CancerBora Lim, David A Potter, Mohamad A Salkeni, et al.
Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.
Cancers|September 9, 2022
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a TrialJohn Hilton, Mihaela Cristea, Sophie Postel-Vinay, et al.
Molecular Cancer Therapeutics|January 30, 2016
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian CancerColin D Weekes, Laetitia E Lamberts, Mitesh J Borad, et al.
Pageof 35

Showing results (321-330 of 344) with videos related to

Sort By:
Pageof 35
Cancer Research Communications|April 6, 2026
Metastasis-Associated Wound Repair Promotes Reciprocal Lung Epithelium Activation and Breast Cancer Metastatic OutgrowthJessica L Christenson, Nicole S Spoelstra, Michelle M Williams, et al.
Biorxiv : the Preprint Server for Biology|December 16, 2024
Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breastJoseph L Sottnik, Madeleine T Shackleford, Camryn S Nesiba, et al.
Cancer Research Communications|March 11, 2026
Metastasis-associated wound repair promotes reciprocal lung epithelium activation and breast cancer metastatic outgrowthJessica L Christenson, Nicole S Spoelstra, Michelle M Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2019
Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4Priscilla K Stumpf, Diana M Cittelly, Tyler P Robin, et al.
Cancer Research|January 9, 2026
Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP InhibitionJoseph L Sottnik, Madeleine T Shackleford, Camryn S Nesiba, et al.
Journal of Neurotrauma|January 8, 2021
Tractography-Pathology Correlations in Traumatic Brain Injury: A TRACK-TBI StudyAmber L Nolan, Cathrine Petersen, Diego Iacono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast CancerBora Lim, David A Potter, Mohamad A Salkeni, et al.
Breast Cancer Research : BCR|August 4, 2018
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancerJennifer R Diamond, S G Eckhardt, Todd M Pitts, et al.
Cancers|September 9, 2022
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a TrialJohn Hilton, Mihaela Cristea, Sophie Postel-Vinay, et al.
Molecular Cancer Therapeutics|January 30, 2016
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian CancerColin D Weekes, Laetitia E Lamberts, Mitesh J Borad, et al.
Pageof 35